The class of weight loss drugs known as GLP-1 treatments have been putting pressure on WeightWatchers
Noyan-Ashraf MH, Momen MA, Ban K et al (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
Discover Blooms Prescriptions: Tailored for You
Obesity is often associated with other chronic conditions, including high cholesterol, high blood pressure, type 2 diabetes, osteoarthritis, and high blood sugar
Usually, as with other drug evaluations, the placebo-adjusted treatment effect (i.e., the difference between weight losses with pharmacotherapy and placebo, when given as an adjunct to lifestyle intervention) is provided from data in randomized clinical trials (RCTs)